Filing Flows › Pfizer (PFE) › Free cash flow
Pfizer (PFE) free cash flow by quarter
Pfizer's free cash flow was $4.8B in Q3 2026 (third quarter 2026), up 16-fold from Q2 2026. Over the last 6 quarters it ranged from $302M (Q2 2026) to $4.8B (Q3 2026).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $4.8B | 16× | +20% |
| Q2 2026 | $302M | -86% | — |
| Q1 2026 | $2.2B | -52% | +23% |
| Q4 2025 | $4.5B | +13% | — |
| Q3 2025 | $4.0B | +126% | — |
| Q1 2025 | $1.8B | — | — |
Q3 2026 at a glance
Pfizer, Q3 2026: revenue $16.6B (-0.4% year over year), operating margin 20.4%, net earnings $3.3B, operating cash flow $5.4B. The chart follows the revenue to costs, profit and cash.
Questions
What is Pfizer's free cash flow?
Pfizer's free cash flow was $4.8B in Q3 2026 (third quarter 2026), up 16-fold from Q2 2026.
How has Pfizer's free cash flow changed?
Over the last 6 quarters it ranged from $302M (Q2 2026) to $4.8B (Q3 2026).